Is there any human RCT data for luteolin?

Small open-label trials exist for luteolin in autism-related neuroinflammation (Theoharides group) and for combined luteolin + quercetin in mast-cell activation syndrome. There is no large placebo-controlled efficacy trial as of mid-2026.

What's the most defensible structure–function claim for a luteolin supplement?

'Supports a healthy inflammatory response' and 'supports antioxidant defense' have the broadest evidentiary backing and are within DSHEA-acceptable language for the US market. Neuroprotection claims should be avoided without a human RCT to back them.

How does luteolin pair with quercetin in formulation?

They're commonly stacked because they target overlapping but distinct inflammatory pathways. Quercetin is more vascular and antihistamine; luteolin is more STAT3 and mast-cell. A 2:1 quercetin:luteolin ratio is common in mast-cell-activation formulations.

Luteolin 2026 Evidence Review: Anti-Inflammatory, Neuroprotective, Antioxidant

A formulator-oriented roundup of the 2023–2025 literature on luteolin's three best-supported mechanisms — and where the human evidence still lags.

TL;DR

Luteolin's evidence base in 2026 is strongest for anti-inflammatory mechanism work, moderate for neuroinflammation and antioxidant defense, and early-stage for cardiovascular and metabolic outcomes. Most of the strong data is still preclinical — formulators should be careful with claims and lean on the mechanism story (which Google indexes well) rather than overstating clinical proof.

This article reviews 30+ papers from 2023–2025 and pulls out the three mechanisms with the deepest support, plus the gaps the field still needs to close.

Why luteolin shows up in formulations now

Luteolin has been in the academic literature for decades, but a few things converged to push it into supplement R&D pipelines around 2023:

The post-2020 "anti-inflammation" supplement category surged, and luteolin has one of the broadest anti-inflammatory mechanism portfolios in the flavonoid family
Theoharides and colleagues published a series of papers linking luteolin to mast-cell-driven neuroinflammation ¹, creating a cleaner narrative for neuro/cognitive positioning than the older generic "antioxidant" story
Better commercial supply (we and 3–4 other Chinese manufacturers can now deliver 95–99.5% HPLC at <$200/kg in bulk) lowered the cost-in-formula

The three best-supported mechanisms

1. Direct anti-inflammatory action via NF-κB / MAPK / STAT3

This is the deepest evidence base. Luteolin demonstrably:

Inhibits NF-κB phosphorylation and nuclear translocation at low micromolar concentrations
Reduces TNF-α, IL-6, IL-1β, and IL-8 production in LPS-stimulated macrophages

A 2018 narrative review covered the foundation; the 2023–2025 literature has tightened mechanism but not added a large human RCT ².

2. Mast cell stabilization → neuroinflammation pathway

This is the most exciting recent area. Mast cell activation in the brain is increasingly implicated in conditions ranging from autism spectrum to long-COVID brain fog to ME/CFS. Theoharides' group has been the strongest voice here:

Luteolin (and luteolin glucoside) reduce mast cell degranulation in vitro at low concentrations
A small open-label trial in autism-related neuroinflammation reported improvements on multiple metrics with a luteolin + quercetin formula ¹
The mechanism story is now publishable enough that mainstream supplement brands (Thorne, Pure Encapsulations) carry luteolin-containing SKUs

3. Antioxidant defense via Nrf2 / ARE / HO-1

Luteolin is a strong direct radical scavenger AND an indirect activator of the Nrf2 pathway, which upregulates endogenous antioxidant enzymes (HO-1, SOD, GSH-Px). This dual mechanism is more durable than direct scavenging alone (radicals only get scavenged once; an upregulated enzyme keeps working).

Where the evidence still lags

No large RCT for any outcome. All human data is small open-label or pilot.
Bioavailability is poorly characterized. Most pharmacokinetic studies are old (pre-2015) and used different formulations.
Cardiovascular outcomes (vascular wellness, blood pressure) show strong preclinical signal ³ but no human efficacy trial.
Uric-acid lowering — promising xanthine oxidase inhibition data but no controlled hyperuricemia trial.

Practical implications for supplement formulation

Lead with mechanism, not outcome. Mechanism stories are now well-documented and search engines (and PAA) reward this; outcome claims invite FTC/FDA scrutiny.
Stack with complementary flavonoids. Luteolin + quercetin + apigenin is a common anti-inflammation stack; rutin adds vascular angle.
Solve bioavailability. Free aglycone luteolin has poor solubility. Phytosomal forms or luteolin-7-O-glucoside (water-soluble) make a real difference for formulators targeting beverages or fast-onset capsules.
Don't sleep on the neuro angle. Even without RCTs, the mast-cell-neuroinflammation narrative is breakout territory for category-leading brands.

Sourcing notes

For bulk luteolin in 2026, the practical qualification criteria haven't changed:

HPLC purity (95% / 98% / 99.5%) — verify with batch COA
Source plant — chrysanthemum vs perilla vs Japanese pagoda; affects flavonoid by-product profile and allergen labeling
ICH Q3C solvent residue compliance
ICP-MS heavy metals (especially for monomer-purified actives — purification can concentrate trace metals from the resin step)

See our Luteolin product page for our spec and pricing, or Quercetin for the most common stacking partner.

References

Theoharides TC (2024). BioFactors. doi:10.1002/biof.2074 ↩ ↩²
Aziz N et al. (2018). J Ethnopharmacol. doi:10.1016/j.jep.2018.07.005 ↩
Wang Z et al. (2023). Pharmacol Res. doi:10.1016/j.phrs.2023.106756 ↩

Luteolin in 2026: what the recent research says (and what it doesn't)